{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-025408","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.669669+00:00","generated_at":"2026-06-05T04:00:00.754710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dyne Therapeutics FY2023 net loss $235.9M; positive DM1/DMD data and $345M offering extend runway to 2025","bullets":["Q4 net loss $66.6M ($1.09/shr) vs $38.8M ($0.74/shr) YoY; FY2023 net loss $235.9M ($3.95/shr).","Cash, equivalents and securities $123.1M at 12/31/23; Jan 2024 $345M public offering (net ~$323.9M) extends runway through 2025.","Initial ACHIEVE (DM1) data: dose-dependent splicing correction and functional myotonia improvement at 1.8 mg/kg dose.","Initial DELIVER (DMD exon 51) data: dystrophin expression exceeded eteplirsen with 24-fold lower total PMO dose; favorable safety.","Plan to report higher-dose cohort data from both trials in H2 2024; goal to initiate registrational cohorts by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-025408","json":"https://secwatch.observer/filing/0000950170-24-025408.json","markdown":"https://secwatch.observer/filing/0000950170-24-025408.md","text":"https://secwatch.observer/filing/0000950170-24-025408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024025408/0000950170-24-025408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024025408/dyn-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:00:00.754710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"586731d583cc9822b71f413d8b1c12a324df59a6","claim":"Dyne Therapeutics, Inc. reported the fourth quarter and full year 2023 results: net income Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share, EPS $1.09 per basic and diluted share.","evidence_excerpt":"Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2023 and recent business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024025408/0000950170-24-025408-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2023"},{"label":"Net income","value":"Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share"},{"label":"EPS","value":"$1.09 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}